Traphagen Investment Advisors LLC Sells 290 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Traphagen Investment Advisors LLC cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 38.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 455 shares of the biopharmaceutical company’s stock after selling 290 shares during the period. Traphagen Investment Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $478,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in REGN. Moss Adams Wealth Advisors LLC increased its stake in Regeneron Pharmaceuticals by 15.7% in the second quarter. Moss Adams Wealth Advisors LLC now owns 419 shares of the biopharmaceutical company’s stock worth $440,000 after purchasing an additional 57 shares during the period. Fifth Third Wealth Advisors LLC lifted its holdings in Regeneron Pharmaceuticals by 76.4% during the 2nd quarter. Fifth Third Wealth Advisors LLC now owns 397 shares of the biopharmaceutical company’s stock valued at $417,000 after buying an additional 172 shares in the last quarter. Argus Investors Counsel Inc. boosted its position in Regeneron Pharmaceuticals by 5.9% in the 2nd quarter. Argus Investors Counsel Inc. now owns 1,551 shares of the biopharmaceutical company’s stock valued at $1,630,000 after buying an additional 86 shares during the period. Aaron Wealth Advisors LLC boosted its position in Regeneron Pharmaceuticals by 71.5% in the 2nd quarter. Aaron Wealth Advisors LLC now owns 403 shares of the biopharmaceutical company’s stock valued at $424,000 after buying an additional 168 shares during the period. Finally, Oak Harvest Investment Services grew its stake in Regeneron Pharmaceuticals by 10.6% in the 2nd quarter. Oak Harvest Investment Services now owns 1,412 shares of the biopharmaceutical company’s stock worth $1,484,000 after acquiring an additional 135 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the transaction, the director now owns 17,882 shares in the company, valued at approximately $18,941,329.68. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 1,172 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $974.86, for a total transaction of $1,142,535.92. Following the sale, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,347,256.52. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the sale, the director now directly owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,731 shares of company stock valued at $18,230,142. 7.48% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on REGN shares. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, August 16th. JPMorgan Chase & Co. upped their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Barclays raised their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,220.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Wells Fargo & Company increased their target price on shares of Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Finally, TD Cowen raised their target price on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $1,104.65.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded up $2.32 during trading hours on Thursday, reaching $1,187.66. The stock had a trading volume of 303,376 shares, compared to its average volume of 471,382. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a twelve month low of $769.19 and a twelve month high of $1,203.49. The stock’s 50 day moving average is $1,081.59 and its 200 day moving average is $1,000.46. The firm has a market capitalization of $130.93 billion, a PE ratio of 35.17, a PEG ratio of 3.12 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. Regeneron Pharmaceuticals’s quarterly revenue was up 12.3% compared to the same quarter last year. During the same period last year, the company earned $8.79 earnings per share. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.